Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September 202 ...

BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...

Change of the Company’s corporate name to Grace Therapeutics, Inc. The Company’s common stock commenced trading under the trading symbol “GRCE” on Nasdaq ... (A-T), for which there are currently no ...

Urogen's UGN-102 presents a $5B market opportunity for bladder cancer treatment, despite risks. Read more about URGN stock ...

Clene met with the U.S. Food and Drug Administration (FDA) on November 1, 2024, in a Type C meeting to discuss the potential for an accelerated approval pathway in ALS ... and the Company’s existing ...

The FDA has granted Jan123 Orphan ... and its Nasdaq ticker symbol was updated to ALTS. On August 26, 2024, the Company appointed Peter Tassiopoulos as CEO. In October, the Board approved the ...

The Company has received approval to list its common shares on the Nasdaq Capital Market under the symbol “ACOG” and is ...

“We also announced that the FDA has approved our IDE application allowing us to move ... InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

TRV045 is an investigational product and is not yet approved by the FDA. Subjects in both studies referenced in this press release were enrolled outside of the United States, and the studies were not ...

In the rainy season of 2020, the Forestry Development Authority (FDA) investigated the scale of abandoned logs in Grand Bassa ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) (“KalVista”), today announced the closing of a synthetic royalty financing agreement with DRI Healthcare Trust (“DRI”) for up to $179 million, comprised ...